RFK Jr is conducting a review of mifepristone, citing a deeply flawed study. The move could be devastating for women
Robert F Kennedy Jr’s health department is conducting a new review of mifepristone, the drug used in the majority of American abortions, claiming that a new study from a conservative thinktank has raised concerns about its safety.
Mifepristone, which was approved by the FDA 25 years ago this month, has repeatedly been proven safe and effective for use terminating pregnancies in both multiple medical trials and in widespread patient use over the past quarter of a century. The report cited by Kennedy, meanwhile, comes from the Ethics and Public Policy Center – a group that applies “the Jewish and Christian traditions” to modern law and pushes back “against the extreme progressive agenda while building a consensus for conservatives” – and was not peer reviewed. The study has been heavily criticized by medical experts for its methodology and lack of transparency regarding how it obtained and analyzed its data. The report appears to have dramatically inflated the rate of serious adverse health outcomes in patients who took mifepristone – in part by seemingly conflating the bleeding that occurs in the normal course of a medication abortion with hemorrhaging, and in part by relying on unclear terminology. The Ethics and Public Policy Center report classified “serious adverse events” as occurring in almost 11% of mifepristone patients. More reliable studies, subject to data transparency, peer review, and a more rigorously honest set of definitions, have found that such adverse health events happen in fewer than 0.5% of users. In a meta-analysis of more than 100 studies, the vast majority found that more than 99% of people who use mifepristone have no serious complications.
Moira Donegan is a Guardian US columnist
